Androgenic Alopecia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Androgenic Alopecia – Pipeline Review, H2 2016’, provides an overview of the Androgenic Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Androgenic Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Androgenic Alopecia

The report reviews pipeline therapeutics for Androgenic Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Androgenic Alopecia therapeutics and enlists all their major and minor projects

The report assesses Androgenic Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Androgenic Alopecia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Allergan Plc

Almirall SA

BiologicsMD Inc

Dong-A Socio Holdings Co Ltd

Histogen Inc

RepliCel Life Sciences Inc

RiverTown Therapeutics Inc

Samumed LLC

Sucampo Pharmaceuticals Inc


Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Androgenic Alopecia Overview 7

Therapeutics Development 8

Pipeline Products for Androgenic Alopecia - Overview 8

Androgenic Alopecia - Therapeutics under Development by Companies 9

Androgenic Alopecia - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Androgenic Alopecia - Products under Development by Companies 13

Androgenic Alopecia - Companies Involved in Therapeutics Development 14

Aclaris Therapeutics Inc 14

Allergan Plc 15

Almirall SA 16

BiologicsMD Inc 17

Dong-A Socio Holdings Co Ltd 18

Histogen Inc 19

RepliCel Life Sciences Inc 20

RiverTown Therapeutics Inc 21

Samumed LLC 22

Sucampo Pharmaceuticals Inc 23

SWITCH Biotech LLC 24

Androgenic Alopecia - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

(cyclosporine A + minoxidil + RT-175) - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

bimatoprost - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BMD-1341 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BRM-421 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CB-0301 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

finasteride - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

finasteride - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HGEN-001 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

RCH-01 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

RK-023 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

setipiprant - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

SM-04554 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule for Androgenic Alopecia - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Androgenic Alopecia - Dormant Projects 58

Androgenic Alopecia - Discontinued Products 59

Androgenic Alopecia - Product Development Milestones 60

Featured News & Press Releases 60

Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles 60

Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01 60

Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan 61

Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial 62

Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial 62

Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia 63

Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient 64

Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research 64

Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 65

Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum 66

May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness 66

Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine 67

Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology 67

Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for Androgenic Alopecia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Androgenic Alopecia – Pipeline by Aclaris Therapeutics Inc, H2 2016 14

Androgenic Alopecia – Pipeline by Allergan Plc, H2 2016 15

Androgenic Alopecia – Pipeline by Almirall SA, H2 2016 16

Androgenic Alopecia – Pipeline by BiologicsMD Inc, H2 2016 17

Androgenic Alopecia – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 18

Androgenic Alopecia – Pipeline by Histogen Inc, H2 2016 19

Androgenic Alopecia – Pipeline by RepliCel Life Sciences Inc, H2 2016 20

Androgenic Alopecia – Pipeline by RiverTown Therapeutics Inc, H2 2016 21

Androgenic Alopecia – Pipeline by Samumed LLC, H2 2016 22

Androgenic Alopecia – Pipeline by Sucampo Pharmaceuticals Inc, H2 2016 23

Androgenic Alopecia – Pipeline by SWITCH Biotech LLC, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Assessment by Combination Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Androgenic Alopecia – Dormant Projects, H2 2016 58

Androgenic Alopecia – Discontinued Products, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for Androgenic Alopecia, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports